Public Health Implications of Gene?environment Interactions in Parkinson?s Disease: A Functional and Epidemiological Perspective

References

[1] Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3–S8

[2] GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis. Lancet Neurol. 2018;17(11):939–53

[3] Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19(2):170–8.

[4] Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011;119(6):866–72.

[5] Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80(22):2035–41.

[6] Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016;8(342):342ra78.

[7] Narayan S, Liew Z, Bronstein JM, Ritz B. Occupational pesticide exposure and risk of Parkinson's disease: A population-based case-control study. Am J Ind Med. 2017;60(9):768–75

[8] Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease. Epigenetics. 2013;8(10):1030–8.

[9] Singleton AB, Hardy J, Traynor BJ, Houlden H. Towards a complete resolution of the genetic architecture of disease. Trends Genet. 2010;26(10):438–42.

[10] Pan-Montojo F, Funk RH. The role of environmental toxins in the etiology of Parkinson’s disease. Neuromolecular Med. 2010;12(4):333–50.

[11] Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016;15(12):1257–72

[12] Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.

[13] Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23(2):1–13.

[14] Braak H, Del Tredici K. Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70(20):1916–25.

[15] Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19(2):170–8.

[16] Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302(5646):841.

[17] Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of GWAS. Lancet Neurol. 2019;18(12):1091–102.

[18] Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045–7.

[19] Xiong Y, Dawson TM, Dawson VL. Models of LRRK2-associated Parkinson’s disease. Adv Neurobiol. 2017;14:163–91.

[20] Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795–803.

[21] Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004;5(2):213–8.

[22] Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11(11):986–98.

[23] Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res. 2005;134(1):109–18.

[24] Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119(6):866–72.

[25] Martinez-Finley EJ, Gavin CE, Aschner M, Gunter TE. Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med. 2013;62:65–75.

[26] Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A. Air pollution and risk of Parkinson’s disease in a large prospective study of women. Environ Health Perspect. 2017;122(9):933–8.

[27] Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010;8(1):e1000298

[28] Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3(12):1301–6.

[29] Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3(4):461–91.

[30] Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005;19(6):533–42.

[31] Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S210–2.

[32] Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6):1469–80.e12.

[33] Ritz B, Paul KC, Bronstein JM. Of Pesticides and Men: a California story of genes and environment in Parkinson’s disease. Curr Environ Health Rep. 2016;3(1):40–52.

[34] Paul KC, Sinsheimer JS, Cockburn M, Bronstein JM, Ritz B. Organophosphate pesticides and PON1 genotypes in Parkinson’s disease. Environ Int. 2018;120:340–9.

[35] Manthripragada AD, Costello S, Cockburn MG, Bronstein JM, Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology. 2010;21(1):87–94

[36] Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson’s disease. NPJ Parkinsons Dis. 2015;1:15001.

[37] Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease. Epigenetics. 2013;8(10):1030–8.

[38] van Heesbeen HJ, Smidt MP. Entanglement of genetics and epigenetics in Parkinson’s disease. Front Neurosci. 2019;13:277.

[39] Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015;30(3):350–8.

[40] Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6):1469–80.e12

[41] Paul KC, Sinsheimer JS, Rhodes SL, Cockburn M, Bronstein JM, Ritz B. Organophosphate pesticides and paraoxonase 1 (PON1) in Parkinson’s disease. Environ Int. 2016;88:192–9.

[42] Weisskopf MG, Weuve J, Nie H, Saint-Hilaire MH, Sudarsky L, Simon DK, et al. Association of cumulative lead exposure with Parkinson’s disease. Environ Health Perspect. 2010;118(11):1609–13.

[43] Kim Y, Kim C, Park M, Kim S, Jang H, Cho J, et al. Urinary biomarkers of pesticide exposure and risk of Parkinson’s disease. Neurotoxicology. 2020;78:174–80.

[44] Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, et al. Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study. BMC Neurol. 2008;8:6.

[45] Firestone JA, Lundin JI, Powers KM, Smith-Weller T, Franklin GM, Swanson PD, et al. Occupational factors and risk of Parkinson’s disease: a population-based case-control study. Am J Ind Med. 2010;53(3):217–23.

[46] Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80(22):2035–41

[47] Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651–61.

[48] Akinyemi RO, Okubadejo NU, Lesi FE. Epidemiology of Parkinsonism and Parkinson’s disease in Sub-Saharan Africa: Nigerian experience. Mov Disord Clin Pract. 2015;2(3):182–5.

[49] Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, et al. Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology. 1996;47(1):155–60.

[50] Mostafalou S, Abdollahi M. Pesticides and human chronic diseases: evidences, mechanisms, and perspectives. Toxicol Appl Pharmacol. 2013;268(2):157–77.

[51] Ross LF, Saal HM, David KL, Anderson RR. Technical report: Ethical and policy issues in genetic testing and screening of children. Genet Med. 2013;15(3):234–45.

[52] Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.

[53] Vineis P, Chadeau-Hyam M, Gmuender H, Gulliver J, Herceg Z, Kleinjans J, et al. The exposome in practice: design of the EXPOsOMICS project. Int J Hyg Environ Health. 2017;220(2):142–51.

[54] Sankar PL, Parker LS. The precision medicine initiative’s All of Us research program: an agenda for research on its ethical, legal, and social issues. Genet Med. 2017;19(7):743–50

[55] Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–50.

[56] Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161–4. https://doi.org/10.1038/538161a

[57] Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, et al. Cerebrospinal fluid, plasma, and saliva biomarkers in Parkinson’s disease. Parkinsonism Relat Disord. 2018;46(Suppl 1):S9–S15.

[58] Kamel F. Paths from pesticide exposure to Parkinson’s disease. Neurotoxicology. 2013;39:222–9

[59] Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Parkinsons Dis. 2013;2013:906274.

[60] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.

[61] Sankar PL, Parker LS. The precision medicine initiative’s All of Us research program: an agenda for research on its ethical, legal, and social issues. Genet Med. 2017;19(7):743–50.

@article{1709807,
      author = {Blessing Agbaza},
      title = {Public Health Implications of Gene?environment Interactions in Parkinson?s Disease: A Functional and Epidemiological Perspective},
      journal = {Iconic Research And Engineering Journals},
      year = {2023},
      volume = {7},
      number = {3},
      pages = {816-825},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1709807.pdf},
      abstract = {Parkinson?s disease (PD) is a progressive neurodegenerative disorder, and we're learning that its causes are tied to a complex mix of genetic factors and environmental influences. While we know that certain genetic mutations and harmful environmental agents can contribute to PD on their own, it?s the interplay between these factors known as gene?environment (G?E) interactions that gives us a fuller picture of the disease's risk, variability, and progression This review aimed at bringing together the latest findings on the molecular mechanisms and epidemiological trends related to G?E interactions in PD, highlighting their importance for real-world applications and public health. By analyzing data from influential functional genomics studies, epidemiological meta-analyses, and population-based cohorts, significant genetic markers (like SNCA, LRRK2, and GBA), environmental neurotoxins (such as pesticides and heavy metals), and new mechanistic pathways, including mitochondrial dysfunction, epigenetic changes, and disruptions in the gut?brain connection was delved into. Insights from precision medicine, biomarker development, and community-focused prevention strategies was woven together.  Research showed that environmental factors like paraquat and organophosphates can work together with genetic weaknesses especially low-activity PON1 variants and LRRK2 mutations to speed up the onset and progression of PD. Epigenetic changes and inflammation driven by gut microbiota play crucial roles in these interactions. Epidemiological studies have pinpointed specific geographical and occupational risk clusters, and meta-analyses support the idea that G?E interactions have a causal impact. However, we still have a gap in data from low- and middle-income countries. Grasping the interactions between genes and the environment in Parkinson's disease opens up vital avenues for identifying risks early, tailoring prevention strategies, and implementing policies that aim to minimize environmental hazards. To truly enhance public health outcomes, future studies should focus on comprehensive, multi-omics methods and ensure fair access to these advancements across various global communities.},
      keywords = {Parkinson?s disease, gene?environment interaction, public health, precision medicine, environmental neurotoxins, mitochondrial dysfunction, LRRK2, PON1, exposomics},
      month = {September},
  }